Does J9153 require prior authorization?

Yes, J9153 requires prior authorization (high confidence). Code explicitly requires prior authorization.

What is the Medicare reimbursement rate for J9153?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J9153`, Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine

HCPCS/CPT

Prior Authorization

Prior Auth Required

Code explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Procedure codes listed are for general reference and may not be all-inclusive.
Benefit coverage/reimbursement determinations must be based on the written coverage position in the Medical Policy, not on the presence or absence of listed codes.

Key Coverage Criteria

Medically necessary when the drug is FDA‑approved and administered in accordance with FDA labeling for an oncologic indication.
Medically necessary when the drug has an NCCN category 1, 2A, or 2B recommendation or is listed in the NCCN Drugs & Biologics Compendium.
Medically necessary when the drug is FDA‑approved and administered in accordance with FDA labeling for an oncologic indication.
Medically necessary when the drug has an NCCN category 1, 2A, or 2B recommendation or is listed in the NCCN Drugs & Biologics Compendium.
Oncology medications are medically necessary if (a) the drug is FDA-approved for the oncologic indication and used per FDA labeling, OR (b) the drug has an NCCN Category 1/2A/2B indication per NCCN Guidelines or NCCN Compendium.
Oncology medications may be considered medically necessary when the drug (a) is FDA-approved for an oncologic indication and used per FDA labeling, or (b) has NCCN Category 1/2A/2B recommendation per NCCN Guidelines or NCCN Compendium.

11 Active Policies

BCBSND-DAUNORUBICIN-AND-CYTARABINE-LIPOSOMAL-VY-3591587724, Daunorubicin AND Cytarabine Liposomal Vyxeos

BCBSNJ-DRUGS-161-711D747DE6, Liposomal Formulation of Daunorubicin and Cytarabine (Vyxeos)

HEALTHNET_OR-HNOR-DAUNORUBICIN-CYTARABINE-VYXEOS-CP-PHAR-352-EB17E60B1B, Daunorubicin/Cytarabine (Vyxeos); CP.PHAR.352

MODA-VYXEOS-3DFD850EF6, Vyxeos (daunorubicin and cytarabine) liposome

BCBSMT-RX502.061, Oncology Medications

BCBSNM-RX502.061, Oncology Medications

EVICORE-HPLAN-CIGNA-729A536F50C8, Q3 - 2026 Cigna MedOnc Master Drug List.pdf

BCBSOK-RX502.061, Oncology Medications

EVICORE-HPLAN-HEALTH_PARTNERS_PLANS-4BC80209CCC5, Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List

BCBSTN-dc9dc8a36a, Daunorubicin and Cytarabine, Liposome (Vyxeos)

BCBSIL-RX502.061, Oncology Medications

`J9153`, Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

11 Active Policies

Related Codes

Have a follow-up question?

J9153, Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

11 Active Policies

Related Codes

Have a follow-up question?

`J9153`, Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine